

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

20-981

APPROVAL LETTER



NDA 20-981

NDA APPROVAL

SmithKline Beecham Corporation d/b/a GlaxoSmithKline
Attention: Philip A. Witman
Associate Director, US Regulatory Affairs, Oncology
One Franklin Plaza
P.O. Box 7929
Philadelphia, PA 19101

Dear Mr. Witman:

Please refer to your new drug application (NDA) dated April 11, 2007, received April 11, 2007, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for HYCAMTIN® (topotecan) Capsules; 0.25 mg and 1 mg.

We acknowledge receipt of your submissions dated July 6, 10, 11 (2), 17, 19, and 26, 2007; August 2, 6, 7, 9, 14, 15, 24, 29, and 31, 2007; September 6, 10, 14, 18, 24, and 25, 2007; October 3 (2), 4, 5, 10 (2) and 11 (electronic), 2007.

This new drug application provides for the use of HYCAMTIN® for the treatment of relapsed small cell lung cancer in patients with a prior complete or partial response and who are at least 45 days from the end of first-line chemotherapy.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

Submit final printed carton and container labels that are identical to the enclosed carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (October 2005)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission **“Final Printed Carton and Container Labels for approved NDA 20-981.”** Approval of this submission by FDA is not required before the labeling is used.

Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

An expiration dating period of 36 months is granted for the drug product when stored at 25°C/
[REDACTED], as described in the labeling.

We recommend that you institute an in-process test with [REDACTED]
[REDACTED]

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described at <http://www.fda.gov/oc/datacouncil/spl.html> that is identical to the enclosed labeling (text for the package insert, text for the patient package insert). Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, "SPL for approved NDA 20-981."

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for this application.

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see www.fda.gov/cder/ddmac.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at: www.fda.gov/medwatch/report/mmp.htm.

If you have any questions, call Kim J. Robertson, Consumer Safety Officer, at (301) 796-1441.

Sincerely,

{See appended electronic signature page}

Robert L. Justice, M.D.
Division Director
Division of Drug Oncology Products
Office of New Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

Enclosure-Labeling

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Robert Justice
10/11/2007 07:15:16 PM